An updated Ebola vaccine: immunogenic, but will it protect?
- PMID: 25817375
- PMCID: PMC6340390
- DOI: 10.1016/S0140-6736(15)60613-4
An updated Ebola vaccine: immunogenic, but will it protect?
Abstract
Comment on
-
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.Lancet. 2015 Jun 6;385(9984):2272-9. doi: 10.1016/S0140-6736(15)60553-0. Epub 2015 Mar 25. Lancet. 2015. PMID: 25817373 Clinical Trial.
References
-
- WHO. Ebola situation report—11 March 2015. 2015. http://apps.who.int/ebola/current-situation/ebola-situation-report-11-ma... (accessed March 16, 2015).
-
- Zhu F-C, Hou L-H, Li J-X, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; published online March 25 10.1016/S0140-6736(15)60553–0. - DOI - PubMed
-
- Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2014; published online December 22 10.1016/S0140-6736(14)62385–0. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
